This Study is a multicenter, non-interventional, observational, ambispective (retrospective-prospective) study to evaluate clinical and demographic characteristics, approaches to therapy in outpatients with COPD and frequent exacerbations in the Russian Federation. Planned number of Study site is 35 outpatient centers with experience of treatment of COPD with frequency exacerbations in about 30 regions in Russia.
Age range
18 Years – 100 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
To describe the baseline Demographic data characterisics of outpatients with moderate and severe COPD.
Timeframe: 52 weeks of retrospective data before visit 1
To describe the baseline Negative lifestyle factors characterisics of outpatients with moderate and severe COPD.
Timeframe: 52 weeks of retrospective data before visit 1
To describe the baseline Anthropometry data characterisics of outpatients with moderate and severe COPD.
Timeframe: 52 weeks of retrospective data before visit 1
To describe the baseline COPD drug treatment duration in previous 52 weeks of outpatients with moderate and severe COPD.
Timeframe: 52 weeks of retrospective data before visit 1
To describe the baseline Cardiovascular diseases of outpatients with moderate and severe COPD.
Timeframe: 52 weeks of retrospective data before visit 1
To describe the baseline other comorbidities of outpatients with moderate and severe COPD.
Timeframe: 52 weeks of retrospective data before visit 1
To describe the baseline Blood eosinophils count of outpatients with moderate and severe COPD.
Timeframe: 52 weeks of retrospective data before visit 1
To describe the baseline mean smoking index .
Timeframe: 52 weeks of retrospective data before visit 1
To describe the baseline mean duration of smoking
Timeframe: 52 weeks of retrospective data before visit 1
To describe the Proportion of patients with overweight
Timeframe: 52 weeks of retrospective data before visit 1
To describe the baseline dosages of COPD drug treatment in previous 52 weeks of outpatients with moderate and severe COPD.
Timeframe: 52 weeks of retrospective data before visit 1
To describe the baseline proportion of patients with heart failure of outpatients with moderate and severe COPD.
Timeframe: 52 weeks of retrospective data before visit 1
To describe the baseline data of LVEF of patients with heart failure of outpatients with moderate and severe COPD.
Timeframe: 52 weeks of retrospective data before visit 1
To describe the baseline proportion of patients with each CKD stage - C1, C2, C3a, C3b, C4, C5 of outpatients with moderate and severe COPD.
Timeframe: 52 weeks of retrospective data before visit 1
To describe the baseline mean office BP (SBP and DBP) measured at Visit 1 of outpatients with moderate and severe COPD.
Timeframe: 52 weeks of retrospective data before visit 1
To describe the baseline proportion of patients with AH by distribution by AH stage (I, II, III), AH degree (1st, 2nd, 3rd) and risk category at Visit 1 of outpatients with moderate and severe COPD.
Timeframe: 52 weeks of retrospective data before visit 1
To describe the baseline proportion of patients with various classes of medications used for treatment of CVD of outpatients with moderate and severe COPD.
Timeframe: 52 weeks of retrospective data before visit 1